nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—CYP3A4—type 2 diabetes mellitus	0.118	0.534	CbGaD
Tacrolimus—ALB—type 2 diabetes mellitus	0.103	0.466	CbGaD
Tacrolimus—ORM1—Nateglinide—type 2 diabetes mellitus	0.048	0.111	CbGbCtD
Tacrolimus—ALB—Gliclazide—type 2 diabetes mellitus	0.0313	0.0722	CbGbCtD
Tacrolimus—ALB—Repaglinide—type 2 diabetes mellitus	0.0295	0.0679	CbGbCtD
Tacrolimus—ALB—Rosiglitazone—type 2 diabetes mellitus	0.0246	0.0566	CbGbCtD
Tacrolimus—ALB—Valsartan—type 2 diabetes mellitus	0.0217	0.05	CbGbCtD
Tacrolimus—CYP3A7—Nateglinide—type 2 diabetes mellitus	0.0216	0.0498	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Nateglinide—type 2 diabetes mellitus	0.0216	0.0498	CbGbCtD
Tacrolimus—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0216	0.0498	CbGbCtD
Tacrolimus—ALB—Nateglinide—type 2 diabetes mellitus	0.0202	0.0465	CbGbCtD
Tacrolimus—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0193	0.0444	CbGbCtD
Tacrolimus—CYP3A5—Nateglinide—type 2 diabetes mellitus	0.0162	0.0374	CbGbCtD
Tacrolimus—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0139	0.0321	CbGbCtD
Tacrolimus—ALB—Glyburide—type 2 diabetes mellitus	0.0136	0.0314	CbGbCtD
Tacrolimus—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.013	0.0298	CbGbCtD
Tacrolimus—ALB—Losartan—type 2 diabetes mellitus	0.0125	0.0287	CbGbCtD
Tacrolimus—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0115	0.0266	CbGbCtD
Tacrolimus—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0106	0.0243	CbGbCtD
Tacrolimus—CYP3A5—Losartan—type 2 diabetes mellitus	0.01	0.0231	CbGbCtD
Tacrolimus—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.00957	0.0221	CbGbCtD
Tacrolimus—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00923	0.0213	CbGbCtD
Tacrolimus—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00835	0.0192	CbGbCtD
Tacrolimus—ABCB1—Glyburide—type 2 diabetes mellitus	0.00713	0.0164	CbGbCtD
Tacrolimus—ABCB1—Losartan—type 2 diabetes mellitus	0.00652	0.015	CbGbCtD
Tacrolimus—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00633	0.0146	CbGbCtD
Tacrolimus—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.00607	0.014	CbGbCtD
Tacrolimus—CYP3A4—Orlistat—type 2 diabetes mellitus	0.00607	0.014	CbGbCtD
Tacrolimus—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.00574	0.0132	CbGbCtD
Tacrolimus—MTOR—leg—type 2 diabetes mellitus	0.00442	0.092	CbGeAlD
Tacrolimus—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00427	0.00985	CbGbCtD
Tacrolimus—MTOR—hindlimb—type 2 diabetes mellitus	0.00395	0.0822	CbGeAlD
Tacrolimus—CYP3A4—Losartan—type 2 diabetes mellitus	0.00391	0.00901	CbGbCtD
Tacrolimus—ABCA5—islet of Langerhans—type 2 diabetes mellitus	0.00233	0.0485	CbGeAlD
Tacrolimus—ABCA5—retina—type 2 diabetes mellitus	0.00199	0.0415	CbGeAlD
Tacrolimus—ABCA5—nephron tubule—type 2 diabetes mellitus	0.00188	0.0391	CbGeAlD
Tacrolimus—ABCA5—pancreas—type 2 diabetes mellitus	0.00164	0.0341	CbGeAlD
Tacrolimus—ABCA5—cortex of kidney—type 2 diabetes mellitus	0.00161	0.0334	CbGeAlD
Tacrolimus—PPP3CA—islet of Langerhans—type 2 diabetes mellitus	0.00157	0.0328	CbGeAlD
Tacrolimus—ABCA5—adipose tissue—type 2 diabetes mellitus	0.00149	0.0309	CbGeAlD
Tacrolimus—PPP3CA—retina—type 2 diabetes mellitus	0.00135	0.028	CbGeAlD
Tacrolimus—PPP3CA—nephron tubule—type 2 diabetes mellitus	0.00127	0.0264	CbGeAlD
Tacrolimus—PPP3CA—cardiovascular system—type 2 diabetes mellitus	0.00114	0.0237	CbGeAlD
Tacrolimus—PPP3CA—kidney—type 2 diabetes mellitus	0.00111	0.0232	CbGeAlD
Tacrolimus—PPP3CA—pancreas—type 2 diabetes mellitus	0.00111	0.023	CbGeAlD
Tacrolimus—PPP3CA—cortex of kidney—type 2 diabetes mellitus	0.00108	0.0226	CbGeAlD
Tacrolimus—ABCA5—liver—type 2 diabetes mellitus	0.00104	0.0217	CbGeAlD
Tacrolimus—PPP3CA—adipose tissue—type 2 diabetes mellitus	0.001	0.0209	CbGeAlD
Tacrolimus—MTOR—retina—type 2 diabetes mellitus	0.000994	0.0207	CbGeAlD
Tacrolimus—FKBP1A—retina—type 2 diabetes mellitus	0.000894	0.0186	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—nephron tubule—type 2 diabetes mellitus	0.000885	0.0184	CbGeAlD
Tacrolimus—MTOR—cardiovascular system—type 2 diabetes mellitus	0.00084	0.0175	CbGeAlD
Tacrolimus—MTOR—kidney—type 2 diabetes mellitus	0.000822	0.0171	CbGeAlD
Tacrolimus—MTOR—pancreas—type 2 diabetes mellitus	0.000817	0.017	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—cortex of kidney—type 2 diabetes mellitus	0.000758	0.0158	CbGeAlD
Tacrolimus—FKBP1A—cardiovascular system—type 2 diabetes mellitus	0.000756	0.0157	CbGeAlD
Tacrolimus—MTOR—adipose tissue—type 2 diabetes mellitus	0.000741	0.0154	CbGeAlD
Tacrolimus—FKBP1A—kidney—type 2 diabetes mellitus	0.00074	0.0154	CbGeAlD
Tacrolimus—FKBP1A—pancreas—type 2 diabetes mellitus	0.000735	0.0153	CbGeAlD
Tacrolimus—FKBP1A—cortex of kidney—type 2 diabetes mellitus	0.00072	0.015	CbGeAlD
Tacrolimus—PPP3CA—liver—type 2 diabetes mellitus	0.000704	0.0147	CbGeAlD
Tacrolimus—FKBP1A—adipose tissue—type 2 diabetes mellitus	0.000667	0.0139	CbGeAlD
Tacrolimus—CYP3A7—liver—type 2 diabetes mellitus	0.000578	0.012	CbGeAlD
Tacrolimus—Everolimus—CYP3A4—type 2 diabetes mellitus	0.000521	0.306	CrCbGaD
Tacrolimus—Pimecrolimus—CYP3A4—type 2 diabetes mellitus	0.000521	0.306	CrCbGaD
Tacrolimus—MTOR—liver—type 2 diabetes mellitus	0.00052	0.0108	CbGeAlD
Tacrolimus—CYP3A7-CYP3A51P—liver—type 2 diabetes mellitus	0.000492	0.0102	CbGeAlD
Tacrolimus—FKBP1A—liver—type 2 diabetes mellitus	0.000467	0.00973	CbGeAlD
Tacrolimus—CYP3A5—islet of Langerhans—type 2 diabetes mellitus	0.000455	0.00948	CbGeAlD
Tacrolimus—CYP3A5—nephron tubule—type 2 diabetes mellitus	0.000366	0.00763	CbGeAlD
Tacrolimus—ORM1—liver—type 2 diabetes mellitus	0.000366	0.00762	CbGeAlD
Tacrolimus—Temsirolimus—CYP3A4—type 2 diabetes mellitus	0.000352	0.207	CrCbGaD
Tacrolimus—CYP3A5—kidney—type 2 diabetes mellitus	0.000322	0.00671	CbGeAlD
Tacrolimus—ALB—liver—type 2 diabetes mellitus	0.000321	0.00668	CbGeAlD
Tacrolimus—CYP3A5—pancreas—type 2 diabetes mellitus	0.00032	0.00666	CbGeAlD
Tacrolimus—CYP3A5—cortex of kidney—type 2 diabetes mellitus	0.000314	0.00653	CbGeAlD
Tacrolimus—Sirolimus—CYP3A4—type 2 diabetes mellitus	0.00031	0.182	CrCbGaD
Tacrolimus—CYP3A5—adipose tissue—type 2 diabetes mellitus	0.00029	0.00604	CbGeAlD
Tacrolimus—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.000242	0.00503	CbGeAlD
Tacrolimus—CYP3A4—kidney—type 2 diabetes mellitus	0.000242	0.00503	CbGeAlD
Tacrolimus—ABCB1—retina—type 2 diabetes mellitus	0.000207	0.0043	CbGeAlD
Tacrolimus—CYP3A5—liver—type 2 diabetes mellitus	0.000204	0.00424	CbGeAlD
Tacrolimus—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000195	0.00405	CbGeAlD
Tacrolimus—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000175	0.00364	CbGeAlD
Tacrolimus—ABCB1—kidney—type 2 diabetes mellitus	0.000171	0.00356	CbGeAlD
Tacrolimus—ABCB1—pancreas—type 2 diabetes mellitus	0.00017	0.00354	CbGeAlD
Tacrolimus—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000167	0.00347	CbGeAlD
Tacrolimus—ABCB1—adipose tissue—type 2 diabetes mellitus	0.000154	0.00321	CbGeAlD
Tacrolimus—CYP3A4—liver—type 2 diabetes mellitus	0.000153	0.00318	CbGeAlD
Tacrolimus—ABCB1—liver—type 2 diabetes mellitus	0.000108	0.00225	CbGeAlD
Tacrolimus—Thrombocytopenia—Metformin—type 2 diabetes mellitus	4.25e-05	0.000224	CcSEcCtD
Tacrolimus—Dyspnoea—Valsartan—type 2 diabetes mellitus	4.24e-05	0.000224	CcSEcCtD
Tacrolimus—Vertigo—Losartan—type 2 diabetes mellitus	4.24e-05	0.000224	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	4.24e-05	0.000224	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	4.24e-05	0.000224	CcSEcCtD
Tacrolimus—Somnolence—Valsartan—type 2 diabetes mellitus	4.23e-05	0.000224	CcSEcCtD
Tacrolimus—Syncope—Losartan—type 2 diabetes mellitus	4.23e-05	0.000224	CcSEcCtD
Tacrolimus—Paraesthesia—Orlistat—type 2 diabetes mellitus	4.22e-05	0.000223	CcSEcCtD
Tacrolimus—Leukopenia—Losartan—type 2 diabetes mellitus	4.22e-05	0.000223	CcSEcCtD
Tacrolimus—Discomfort—Irbesartan—type 2 diabetes mellitus	4.22e-05	0.000223	CcSEcCtD
Tacrolimus—Skin disorder—Metformin—type 2 diabetes mellitus	4.21e-05	0.000223	CcSEcCtD
Tacrolimus—Immune system disorder—Ramipril—type 2 diabetes mellitus	4.2e-05	0.000222	CcSEcCtD
Tacrolimus—Hyperhidrosis—Metformin—type 2 diabetes mellitus	4.19e-05	0.000222	CcSEcCtD
Tacrolimus—Dyspepsia—Valsartan—type 2 diabetes mellitus	4.19e-05	0.000222	CcSEcCtD
Tacrolimus—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	4.19e-05	0.000221	CcSEcCtD
Tacrolimus—Dizziness—Bromocriptine—type 2 diabetes mellitus	4.17e-05	0.000221	CcSEcCtD
Tacrolimus—Dry mouth—Irbesartan—type 2 diabetes mellitus	4.17e-05	0.000221	CcSEcCtD
Tacrolimus—Palpitations—Losartan—type 2 diabetes mellitus	4.17e-05	0.00022	CcSEcCtD
Tacrolimus—Nausea—Glimepiride—type 2 diabetes mellitus	4.16e-05	0.00022	CcSEcCtD
Tacrolimus—Arrhythmia—Ramipril—type 2 diabetes mellitus	4.15e-05	0.000219	CcSEcCtD
Tacrolimus—Loss of consciousness—Losartan—type 2 diabetes mellitus	4.15e-05	0.000219	CcSEcCtD
Tacrolimus—Nausea—Sitagliptin—type 2 diabetes mellitus	4.14e-05	0.000219	CcSEcCtD
Tacrolimus—Dyspepsia—Orlistat—type 2 diabetes mellitus	4.14e-05	0.000219	CcSEcCtD
Tacrolimus—Asthenia—Glyburide—type 2 diabetes mellitus	4.14e-05	0.000219	CcSEcCtD
Tacrolimus—Decreased appetite—Valsartan—type 2 diabetes mellitus	4.14e-05	0.000219	CcSEcCtD
Tacrolimus—Anorexia—Metformin—type 2 diabetes mellitus	4.13e-05	0.000218	CcSEcCtD
Tacrolimus—Cough—Losartan—type 2 diabetes mellitus	4.12e-05	0.000218	CcSEcCtD
Tacrolimus—Urticaria—Gliclazide—type 2 diabetes mellitus	4.12e-05	0.000218	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	4.11e-05	0.000217	CcSEcCtD
Tacrolimus—Alopecia—Ramipril—type 2 diabetes mellitus	4.11e-05	0.000217	CcSEcCtD
Tacrolimus—Fatigue—Valsartan—type 2 diabetes mellitus	4.1e-05	0.000217	CcSEcCtD
Tacrolimus—Body temperature increased—Gliclazide—type 2 diabetes mellitus	4.1e-05	0.000217	CcSEcCtD
Tacrolimus—Abdominal pain—Gliclazide—type 2 diabetes mellitus	4.1e-05	0.000217	CcSEcCtD
Tacrolimus—Oedema—Irbesartan—type 2 diabetes mellitus	4.09e-05	0.000216	CcSEcCtD
Tacrolimus—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	4.09e-05	0.000216	CcSEcCtD
Tacrolimus—Decreased appetite—Orlistat—type 2 diabetes mellitus	4.09e-05	0.000216	CcSEcCtD
Tacrolimus—Pruritus—Glyburide—type 2 diabetes mellitus	4.08e-05	0.000216	CcSEcCtD
Tacrolimus—Mental disorder—Ramipril—type 2 diabetes mellitus	4.07e-05	0.000215	CcSEcCtD
Tacrolimus—Constipation—Valsartan—type 2 diabetes mellitus	4.07e-05	0.000215	CcSEcCtD
Tacrolimus—Infection—Irbesartan—type 2 diabetes mellitus	4.06e-05	0.000215	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	4.06e-05	0.000215	CcSEcCtD
Tacrolimus—Fatigue—Orlistat—type 2 diabetes mellitus	4.06e-05	0.000214	CcSEcCtD
Tacrolimus—Hypotension—Metformin—type 2 diabetes mellitus	4.05e-05	0.000214	CcSEcCtD
Tacrolimus—Erythema—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000214	CcSEcCtD
Tacrolimus—Malnutrition—Ramipril—type 2 diabetes mellitus	4.05e-05	0.000214	CcSEcCtD
Tacrolimus—Shock—Irbesartan—type 2 diabetes mellitus	4.03e-05	0.000213	CcSEcCtD
Tacrolimus—Pain—Orlistat—type 2 diabetes mellitus	4.02e-05	0.000213	CcSEcCtD
Tacrolimus—Arthralgia—Losartan—type 2 diabetes mellitus	4.02e-05	0.000212	CcSEcCtD
Tacrolimus—Chest pain—Losartan—type 2 diabetes mellitus	4.02e-05	0.000212	CcSEcCtD
Tacrolimus—Myalgia—Losartan—type 2 diabetes mellitus	4.02e-05	0.000212	CcSEcCtD
Tacrolimus—Vomiting—Bromocriptine—type 2 diabetes mellitus	4.01e-05	0.000212	CcSEcCtD
Tacrolimus—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	4.01e-05	0.000212	CcSEcCtD
Tacrolimus—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	4.01e-05	0.000212	CcSEcCtD
Tacrolimus—Anxiety—Losartan—type 2 diabetes mellitus	4e-05	0.000212	CcSEcCtD
Tacrolimus—Tachycardia—Irbesartan—type 2 diabetes mellitus	3.99e-05	0.000211	CcSEcCtD
Tacrolimus—Rash—Bromocriptine—type 2 diabetes mellitus	3.98e-05	0.00021	CcSEcCtD
Tacrolimus—Dermatitis—Bromocriptine—type 2 diabetes mellitus	3.98e-05	0.00021	CcSEcCtD
Tacrolimus—Skin disorder—Irbesartan—type 2 diabetes mellitus	3.97e-05	0.00021	CcSEcCtD
Tacrolimus—Tension—Ramipril—type 2 diabetes mellitus	3.97e-05	0.00021	CcSEcCtD
Tacrolimus—Discomfort—Losartan—type 2 diabetes mellitus	3.97e-05	0.00021	CcSEcCtD
Tacrolimus—Dysgeusia—Ramipril—type 2 diabetes mellitus	3.96e-05	0.000209	CcSEcCtD
Tacrolimus—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	3.96e-05	0.000209	CcSEcCtD
Tacrolimus—Headache—Bromocriptine—type 2 diabetes mellitus	3.95e-05	0.000209	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	3.95e-05	0.000209	CcSEcCtD
Tacrolimus—Diarrhoea—Glyburide—type 2 diabetes mellitus	3.95e-05	0.000209	CcSEcCtD
Tacrolimus—Nervousness—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000208	CcSEcCtD
Tacrolimus—Dry mouth—Losartan—type 2 diabetes mellitus	3.93e-05	0.000208	CcSEcCtD
Tacrolimus—Anorexia—Irbesartan—type 2 diabetes mellitus	3.9e-05	0.000206	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	3.89e-05	0.000206	CcSEcCtD
Tacrolimus—Paraesthesia—Metformin—type 2 diabetes mellitus	3.89e-05	0.000206	CcSEcCtD
Tacrolimus—Muscle spasms—Ramipril—type 2 diabetes mellitus	3.89e-05	0.000206	CcSEcCtD
Tacrolimus—Confusional state—Losartan—type 2 diabetes mellitus	3.88e-05	0.000205	CcSEcCtD
Tacrolimus—Feeling abnormal—Orlistat—type 2 diabetes mellitus	3.88e-05	0.000205	CcSEcCtD
Tacrolimus—Dyspnoea—Metformin—type 2 diabetes mellitus	3.87e-05	0.000204	CcSEcCtD
Tacrolimus—Somnolence—Metformin—type 2 diabetes mellitus	3.85e-05	0.000204	CcSEcCtD
Tacrolimus—Oedema—Losartan—type 2 diabetes mellitus	3.85e-05	0.000204	CcSEcCtD
Tacrolimus—Anaphylactic shock—Losartan—type 2 diabetes mellitus	3.85e-05	0.000204	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	3.85e-05	0.000203	CcSEcCtD
Tacrolimus—Infection—Losartan—type 2 diabetes mellitus	3.83e-05	0.000202	CcSEcCtD
Tacrolimus—Hypotension—Irbesartan—type 2 diabetes mellitus	3.82e-05	0.000202	CcSEcCtD
Tacrolimus—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	3.82e-05	0.000202	CcSEcCtD
Tacrolimus—Dyspepsia—Metformin—type 2 diabetes mellitus	3.82e-05	0.000202	CcSEcCtD
Tacrolimus—Tremor—Ramipril—type 2 diabetes mellitus	3.79e-05	0.0002	CcSEcCtD
Tacrolimus—Shock—Losartan—type 2 diabetes mellitus	3.79e-05	0.0002	CcSEcCtD
Tacrolimus—Urticaria—Valsartan—type 2 diabetes mellitus	3.78e-05	0.0002	CcSEcCtD
Tacrolimus—Nervous system disorder—Losartan—type 2 diabetes mellitus	3.78e-05	0.0002	CcSEcCtD
Tacrolimus—Thrombocytopenia—Losartan—type 2 diabetes mellitus	3.77e-05	0.000199	CcSEcCtD
Tacrolimus—Decreased appetite—Metformin—type 2 diabetes mellitus	3.77e-05	0.000199	CcSEcCtD
Tacrolimus—Abdominal pain—Valsartan—type 2 diabetes mellitus	3.76e-05	0.000199	CcSEcCtD
Tacrolimus—Tachycardia—Losartan—type 2 diabetes mellitus	3.76e-05	0.000199	CcSEcCtD
Tacrolimus—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	3.75e-05	0.000198	CcSEcCtD
Tacrolimus—Nausea—Bromocriptine—type 2 diabetes mellitus	3.75e-05	0.000198	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	3.74e-05	0.000198	CcSEcCtD
Tacrolimus—Fatigue—Metformin—type 2 diabetes mellitus	3.74e-05	0.000198	CcSEcCtD
Tacrolimus—Urticaria—Orlistat—type 2 diabetes mellitus	3.74e-05	0.000198	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	3.73e-05	0.000197	CcSEcCtD
Tacrolimus—Hyperhidrosis—Losartan—type 2 diabetes mellitus	3.72e-05	0.000197	CcSEcCtD
Tacrolimus—Abdominal pain—Orlistat—type 2 diabetes mellitus	3.72e-05	0.000197	CcSEcCtD
Tacrolimus—Body temperature increased—Orlistat—type 2 diabetes mellitus	3.72e-05	0.000197	CcSEcCtD
Tacrolimus—Asthenia—Gliclazide—type 2 diabetes mellitus	3.72e-05	0.000197	CcSEcCtD
Tacrolimus—Agitation—Ramipril—type 2 diabetes mellitus	3.72e-05	0.000197	CcSEcCtD
Tacrolimus—Constipation—Metformin—type 2 diabetes mellitus	3.71e-05	0.000196	CcSEcCtD
Tacrolimus—Paraesthesia—Irbesartan—type 2 diabetes mellitus	3.67e-05	0.000194	CcSEcCtD
Tacrolimus—Anorexia—Losartan—type 2 diabetes mellitus	3.67e-05	0.000194	CcSEcCtD
Tacrolimus—Vomiting—Glyburide—type 2 diabetes mellitus	3.67e-05	0.000194	CcSEcCtD
Tacrolimus—Pruritus—Gliclazide—type 2 diabetes mellitus	3.67e-05	0.000194	CcSEcCtD
Tacrolimus—Malaise—Ramipril—type 2 diabetes mellitus	3.65e-05	0.000193	CcSEcCtD
Tacrolimus—Dyspnoea—Irbesartan—type 2 diabetes mellitus	3.65e-05	0.000193	CcSEcCtD
Tacrolimus—Rash—Glyburide—type 2 diabetes mellitus	3.64e-05	0.000192	CcSEcCtD
Tacrolimus—Somnolence—Irbesartan—type 2 diabetes mellitus	3.64e-05	0.000192	CcSEcCtD
Tacrolimus—Dermatitis—Glyburide—type 2 diabetes mellitus	3.64e-05	0.000192	CcSEcCtD
Tacrolimus—Vertigo—Ramipril—type 2 diabetes mellitus	3.63e-05	0.000192	CcSEcCtD
Tacrolimus—Syncope—Ramipril—type 2 diabetes mellitus	3.63e-05	0.000192	CcSEcCtD
Tacrolimus—Leukopenia—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000191	CcSEcCtD
Tacrolimus—Headache—Glyburide—type 2 diabetes mellitus	3.62e-05	0.000191	CcSEcCtD
Tacrolimus—Dyspepsia—Irbesartan—type 2 diabetes mellitus	3.6e-05	0.00019	CcSEcCtD
Tacrolimus—Hypotension—Losartan—type 2 diabetes mellitus	3.6e-05	0.00019	CcSEcCtD
Tacrolimus—Palpitations—Ramipril—type 2 diabetes mellitus	3.58e-05	0.000189	CcSEcCtD
Tacrolimus—Feeling abnormal—Metformin—type 2 diabetes mellitus	3.57e-05	0.000189	CcSEcCtD
Tacrolimus—Decreased appetite—Irbesartan—type 2 diabetes mellitus	3.56e-05	0.000188	CcSEcCtD
Tacrolimus—Loss of consciousness—Ramipril—type 2 diabetes mellitus	3.56e-05	0.000188	CcSEcCtD
Tacrolimus—Diarrhoea—Gliclazide—type 2 diabetes mellitus	3.55e-05	0.000187	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	3.55e-05	0.000187	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	3.53e-05	0.000187	CcSEcCtD
Tacrolimus—Cough—Ramipril—type 2 diabetes mellitus	3.53e-05	0.000187	CcSEcCtD
Tacrolimus—Fatigue—Irbesartan—type 2 diabetes mellitus	3.53e-05	0.000186	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	3.51e-05	0.000185	CcSEcCtD
Tacrolimus—Hypersensitivity—Valsartan—type 2 diabetes mellitus	3.51e-05	0.000185	CcSEcCtD
Tacrolimus—Convulsion—Ramipril—type 2 diabetes mellitus	3.51e-05	0.000185	CcSEcCtD
Tacrolimus—Constipation—Irbesartan—type 2 diabetes mellitus	3.5e-05	0.000185	CcSEcCtD
Tacrolimus—Pain—Irbesartan—type 2 diabetes mellitus	3.5e-05	0.000185	CcSEcCtD
Tacrolimus—Insomnia—Losartan—type 2 diabetes mellitus	3.48e-05	0.000184	CcSEcCtD
Tacrolimus—Hypersensitivity—Orlistat—type 2 diabetes mellitus	3.47e-05	0.000183	CcSEcCtD
Tacrolimus—Paraesthesia—Losartan—type 2 diabetes mellitus	3.46e-05	0.000183	CcSEcCtD
Tacrolimus—Urticaria—Metformin—type 2 diabetes mellitus	3.44e-05	0.000182	CcSEcCtD
Tacrolimus—Chest pain—Ramipril—type 2 diabetes mellitus	3.44e-05	0.000182	CcSEcCtD
Tacrolimus—Arthralgia—Ramipril—type 2 diabetes mellitus	3.44e-05	0.000182	CcSEcCtD
Tacrolimus—Myalgia—Ramipril—type 2 diabetes mellitus	3.44e-05	0.000182	CcSEcCtD
Tacrolimus—Dyspnoea—Losartan—type 2 diabetes mellitus	3.43e-05	0.000181	CcSEcCtD
Tacrolimus—Anxiety—Ramipril—type 2 diabetes mellitus	3.43e-05	0.000181	CcSEcCtD
Tacrolimus—Nausea—Glyburide—type 2 diabetes mellitus	3.43e-05	0.000181	CcSEcCtD
Tacrolimus—Abdominal pain—Metformin—type 2 diabetes mellitus	3.43e-05	0.000181	CcSEcCtD
Tacrolimus—Dizziness—Gliclazide—type 2 diabetes mellitus	3.43e-05	0.000181	CcSEcCtD
Tacrolimus—Somnolence—Losartan—type 2 diabetes mellitus	3.42e-05	0.000181	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	3.42e-05	0.000181	CcSEcCtD
Tacrolimus—Asthenia—Valsartan—type 2 diabetes mellitus	3.42e-05	0.000181	CcSEcCtD
Tacrolimus—Discomfort—Ramipril—type 2 diabetes mellitus	3.4e-05	0.00018	CcSEcCtD
Tacrolimus—Dyspepsia—Losartan—type 2 diabetes mellitus	3.39e-05	0.000179	CcSEcCtD
Tacrolimus—Asthenia—Orlistat—type 2 diabetes mellitus	3.38e-05	0.000178	CcSEcCtD
Tacrolimus—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	3.37e-05	0.000178	CcSEcCtD
Tacrolimus—Pruritus—Valsartan—type 2 diabetes mellitus	3.37e-05	0.000178	CcSEcCtD
Tacrolimus—Dry mouth—Ramipril—type 2 diabetes mellitus	3.37e-05	0.000178	CcSEcCtD
Tacrolimus—Decreased appetite—Losartan—type 2 diabetes mellitus	3.35e-05	0.000177	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	3.35e-05	0.000177	CcSEcCtD
Tacrolimus—Confusional state—Ramipril—type 2 diabetes mellitus	3.33e-05	0.000176	CcSEcCtD
Tacrolimus—Pruritus—Orlistat—type 2 diabetes mellitus	3.33e-05	0.000176	CcSEcCtD
Tacrolimus—Fatigue—Losartan—type 2 diabetes mellitus	3.32e-05	0.000175	CcSEcCtD
Tacrolimus—Oedema—Ramipril—type 2 diabetes mellitus	3.3e-05	0.000175	CcSEcCtD
Tacrolimus—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	3.3e-05	0.000175	CcSEcCtD
Tacrolimus—Vomiting—Gliclazide—type 2 diabetes mellitus	3.29e-05	0.000174	CcSEcCtD
Tacrolimus—Pain—Losartan—type 2 diabetes mellitus	3.29e-05	0.000174	CcSEcCtD
Tacrolimus—Constipation—Losartan—type 2 diabetes mellitus	3.29e-05	0.000174	CcSEcCtD
Tacrolimus—Rash—Gliclazide—type 2 diabetes mellitus	3.27e-05	0.000173	CcSEcCtD
Tacrolimus—Dermatitis—Gliclazide—type 2 diabetes mellitus	3.26e-05	0.000173	CcSEcCtD
Tacrolimus—Diarrhoea—Valsartan—type 2 diabetes mellitus	3.26e-05	0.000172	CcSEcCtD
Tacrolimus—Urticaria—Irbesartan—type 2 diabetes mellitus	3.25e-05	0.000172	CcSEcCtD
Tacrolimus—Shock—Ramipril—type 2 diabetes mellitus	3.25e-05	0.000172	CcSEcCtD
Tacrolimus—Headache—Gliclazide—type 2 diabetes mellitus	3.25e-05	0.000172	CcSEcCtD
Tacrolimus—Nervous system disorder—Ramipril—type 2 diabetes mellitus	3.24e-05	0.000171	CcSEcCtD
Tacrolimus—Body temperature increased—Irbesartan—type 2 diabetes mellitus	3.23e-05	0.000171	CcSEcCtD
Tacrolimus—Abdominal pain—Irbesartan—type 2 diabetes mellitus	3.23e-05	0.000171	CcSEcCtD
Tacrolimus—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	3.23e-05	0.000171	CcSEcCtD
Tacrolimus—Tachycardia—Ramipril—type 2 diabetes mellitus	3.22e-05	0.00017	CcSEcCtD
Tacrolimus—Diarrhoea—Orlistat—type 2 diabetes mellitus	3.22e-05	0.00017	CcSEcCtD
Tacrolimus—Skin disorder—Ramipril—type 2 diabetes mellitus	3.21e-05	0.00017	CcSEcCtD
Tacrolimus—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	3.19e-05	0.000169	CcSEcCtD
Tacrolimus—Feeling abnormal—Losartan—type 2 diabetes mellitus	3.17e-05	0.000168	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	3.15e-05	0.000166	CcSEcCtD
Tacrolimus—Dizziness—Valsartan—type 2 diabetes mellitus	3.15e-05	0.000166	CcSEcCtD
Tacrolimus—Anorexia—Ramipril—type 2 diabetes mellitus	3.15e-05	0.000166	CcSEcCtD
Tacrolimus—Dizziness—Orlistat—type 2 diabetes mellitus	3.11e-05	0.000164	CcSEcCtD
Tacrolimus—Asthenia—Metformin—type 2 diabetes mellitus	3.11e-05	0.000164	CcSEcCtD
Tacrolimus—Hypotension—Ramipril—type 2 diabetes mellitus	3.09e-05	0.000163	CcSEcCtD
Tacrolimus—Nausea—Gliclazide—type 2 diabetes mellitus	3.08e-05	0.000163	CcSEcCtD
Tacrolimus—Pruritus—Metformin—type 2 diabetes mellitus	3.07e-05	0.000162	CcSEcCtD
Tacrolimus—Urticaria—Losartan—type 2 diabetes mellitus	3.06e-05	0.000162	CcSEcCtD
Tacrolimus—Abdominal pain—Losartan—type 2 diabetes mellitus	3.04e-05	0.000161	CcSEcCtD
Tacrolimus—Body temperature increased—Losartan—type 2 diabetes mellitus	3.04e-05	0.000161	CcSEcCtD
Tacrolimus—Vomiting—Valsartan—type 2 diabetes mellitus	3.03e-05	0.00016	CcSEcCtD
Tacrolimus—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	3.01e-05	0.000159	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	3.01e-05	0.000159	CcSEcCtD
Tacrolimus—Rash—Valsartan—type 2 diabetes mellitus	3e-05	0.000159	CcSEcCtD
Tacrolimus—Dermatitis—Valsartan—type 2 diabetes mellitus	3e-05	0.000159	CcSEcCtD
Tacrolimus—Vomiting—Orlistat—type 2 diabetes mellitus	2.99e-05	0.000158	CcSEcCtD
Tacrolimus—Insomnia—Ramipril—type 2 diabetes mellitus	2.99e-05	0.000158	CcSEcCtD
Tacrolimus—Headache—Valsartan—type 2 diabetes mellitus	2.98e-05	0.000158	CcSEcCtD
Tacrolimus—Diarrhoea—Metformin—type 2 diabetes mellitus	2.97e-05	0.000157	CcSEcCtD
Tacrolimus—Rash—Orlistat—type 2 diabetes mellitus	2.97e-05	0.000157	CcSEcCtD
Tacrolimus—Paraesthesia—Ramipril—type 2 diabetes mellitus	2.96e-05	0.000157	CcSEcCtD
Tacrolimus—Dermatitis—Orlistat—type 2 diabetes mellitus	2.96e-05	0.000157	CcSEcCtD
Tacrolimus—Headache—Orlistat—type 2 diabetes mellitus	2.95e-05	0.000156	CcSEcCtD
Tacrolimus—Dyspnoea—Ramipril—type 2 diabetes mellitus	2.94e-05	0.000156	CcSEcCtD
Tacrolimus—Asthenia—Irbesartan—type 2 diabetes mellitus	2.94e-05	0.000155	CcSEcCtD
Tacrolimus—Somnolence—Ramipril—type 2 diabetes mellitus	2.94e-05	0.000155	CcSEcCtD
Tacrolimus—Dyspepsia—Ramipril—type 2 diabetes mellitus	2.91e-05	0.000154	CcSEcCtD
Tacrolimus—Pruritus—Irbesartan—type 2 diabetes mellitus	2.89e-05	0.000153	CcSEcCtD
Tacrolimus—Decreased appetite—Ramipril—type 2 diabetes mellitus	2.87e-05	0.000152	CcSEcCtD
Tacrolimus—Dizziness—Metformin—type 2 diabetes mellitus	2.87e-05	0.000152	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	2.85e-05	0.000151	CcSEcCtD
Tacrolimus—Fatigue—Ramipril—type 2 diabetes mellitus	2.85e-05	0.00015	CcSEcCtD
Tacrolimus—Hypersensitivity—Losartan—type 2 diabetes mellitus	2.84e-05	0.00015	CcSEcCtD
Tacrolimus—Nausea—Valsartan—type 2 diabetes mellitus	2.83e-05	0.000149	CcSEcCtD
Tacrolimus—Constipation—Ramipril—type 2 diabetes mellitus	2.82e-05	0.000149	CcSEcCtD
Tacrolimus—Diarrhoea—Irbesartan—type 2 diabetes mellitus	2.8e-05	0.000148	CcSEcCtD
Tacrolimus—Nausea—Orlistat—type 2 diabetes mellitus	2.79e-05	0.000148	CcSEcCtD
Tacrolimus—Asthenia—Losartan—type 2 diabetes mellitus	2.76e-05	0.000146	CcSEcCtD
Tacrolimus—Vomiting—Metformin—type 2 diabetes mellitus	2.76e-05	0.000146	CcSEcCtD
Tacrolimus—Rash—Metformin—type 2 diabetes mellitus	2.73e-05	0.000145	CcSEcCtD
Tacrolimus—Dermatitis—Metformin—type 2 diabetes mellitus	2.73e-05	0.000144	CcSEcCtD
Tacrolimus—Pruritus—Losartan—type 2 diabetes mellitus	2.72e-05	0.000144	CcSEcCtD
Tacrolimus—Feeling abnormal—Ramipril—type 2 diabetes mellitus	2.72e-05	0.000144	CcSEcCtD
Tacrolimus—Headache—Metformin—type 2 diabetes mellitus	2.72e-05	0.000144	CcSEcCtD
Tacrolimus—Dizziness—Irbesartan—type 2 diabetes mellitus	2.71e-05	0.000143	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	2.7e-05	0.000143	CcSEcCtD
Tacrolimus—Diarrhoea—Losartan—type 2 diabetes mellitus	2.63e-05	0.000139	CcSEcCtD
Tacrolimus—Urticaria—Ramipril—type 2 diabetes mellitus	2.62e-05	0.000139	CcSEcCtD
Tacrolimus—Abdominal pain—Ramipril—type 2 diabetes mellitus	2.61e-05	0.000138	CcSEcCtD
Tacrolimus—Body temperature increased—Ramipril—type 2 diabetes mellitus	2.61e-05	0.000138	CcSEcCtD
Tacrolimus—Vomiting—Irbesartan—type 2 diabetes mellitus	2.6e-05	0.000138	CcSEcCtD
Tacrolimus—Rash—Irbesartan—type 2 diabetes mellitus	2.58e-05	0.000136	CcSEcCtD
Tacrolimus—Dermatitis—Irbesartan—type 2 diabetes mellitus	2.58e-05	0.000136	CcSEcCtD
Tacrolimus—Nausea—Metformin—type 2 diabetes mellitus	2.58e-05	0.000136	CcSEcCtD
Tacrolimus—Headache—Irbesartan—type 2 diabetes mellitus	2.56e-05	0.000135	CcSEcCtD
Tacrolimus—Dizziness—Losartan—type 2 diabetes mellitus	2.55e-05	0.000135	CcSEcCtD
Tacrolimus—Vomiting—Losartan—type 2 diabetes mellitus	2.45e-05	0.000129	CcSEcCtD
Tacrolimus—Hypersensitivity—Ramipril—type 2 diabetes mellitus	2.43e-05	0.000129	CcSEcCtD
Tacrolimus—Nausea—Irbesartan—type 2 diabetes mellitus	2.43e-05	0.000128	CcSEcCtD
Tacrolimus—Rash—Losartan—type 2 diabetes mellitus	2.43e-05	0.000128	CcSEcCtD
Tacrolimus—Dermatitis—Losartan—type 2 diabetes mellitus	2.43e-05	0.000128	CcSEcCtD
Tacrolimus—Headache—Losartan—type 2 diabetes mellitus	2.41e-05	0.000128	CcSEcCtD
Tacrolimus—Asthenia—Ramipril—type 2 diabetes mellitus	2.37e-05	0.000125	CcSEcCtD
Tacrolimus—Pruritus—Ramipril—type 2 diabetes mellitus	2.34e-05	0.000123	CcSEcCtD
Tacrolimus—Nausea—Losartan—type 2 diabetes mellitus	2.29e-05	0.000121	CcSEcCtD
Tacrolimus—Diarrhoea—Ramipril—type 2 diabetes mellitus	2.26e-05	0.000119	CcSEcCtD
Tacrolimus—Dizziness—Ramipril—type 2 diabetes mellitus	2.18e-05	0.000115	CcSEcCtD
Tacrolimus—Vomiting—Ramipril—type 2 diabetes mellitus	2.1e-05	0.000111	CcSEcCtD
Tacrolimus—Rash—Ramipril—type 2 diabetes mellitus	2.08e-05	0.00011	CcSEcCtD
Tacrolimus—Dermatitis—Ramipril—type 2 diabetes mellitus	2.08e-05	0.00011	CcSEcCtD
Tacrolimus—Headache—Ramipril—type 2 diabetes mellitus	2.07e-05	0.000109	CcSEcCtD
Tacrolimus—Nausea—Ramipril—type 2 diabetes mellitus	1.96e-05	0.000104	CcSEcCtD
Tacrolimus—CYP3A7—Metabolism—CD36—type 2 diabetes mellitus	4.66e-06	4.43e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOS3—type 2 diabetes mellitus	4.66e-06	4.43e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3R1—type 2 diabetes mellitus	4.66e-06	4.43e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.66e-06	4.42e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.61e-06	4.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPP2CA—type 2 diabetes mellitus	4.6e-06	4.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CYP3A4—type 2 diabetes mellitus	4.6e-06	4.37e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	4.59e-06	4.36e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GCG—type 2 diabetes mellitus	4.52e-06	4.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC2A4—type 2 diabetes mellitus	4.52e-06	4.29e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	4.5e-06	4.27e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	4.5e-06	4.27e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SREBF1—type 2 diabetes mellitus	4.49e-06	4.26e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PSMD6—type 2 diabetes mellitus	4.49e-06	4.26e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SNAP25—type 2 diabetes mellitus	4.49e-06	4.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	4.49e-06	4.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	4.49e-06	4.26e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	4.49e-06	4.26e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.46e-06	4.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.45e-06	4.23e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AGT—type 2 diabetes mellitus	4.45e-06	4.22e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—MTHFR—type 2 diabetes mellitus	4.42e-06	4.19e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	4.41e-06	4.19e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CTGF—type 2 diabetes mellitus	4.41e-06	4.18e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	4.38e-06	4.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	4.38e-06	4.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	4.38e-06	4.16e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.37e-06	4.15e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HMGCR—type 2 diabetes mellitus	4.37e-06	4.15e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	4.36e-06	4.14e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOE—type 2 diabetes mellitus	4.36e-06	4.14e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—LEP—type 2 diabetes mellitus	4.36e-06	4.14e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARA—type 2 diabetes mellitus	4.33e-06	4.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—IL6—type 2 diabetes mellitus	4.32e-06	4.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.31e-06	4.09e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3R1—type 2 diabetes mellitus	4.31e-06	4.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	4.3e-06	4.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	4.3e-06	4.09e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.29e-06	4.08e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	4.28e-06	4.06e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ADRA2A—type 2 diabetes mellitus	4.27e-06	4.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—type 2 diabetes mellitus	4.26e-06	4.05e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	4.23e-06	4.02e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	4.22e-06	4.01e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AGT—type 2 diabetes mellitus	4.2e-06	3.99e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.18e-06	3.97e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	4.15e-06	3.94e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	4.14e-06	3.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	4.14e-06	3.93e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—IL6—type 2 diabetes mellitus	4.13e-06	3.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—CALM1—type 2 diabetes mellitus	4.13e-06	3.92e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOE—type 2 diabetes mellitus	4.11e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.11e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP2E1—type 2 diabetes mellitus	4.11e-06	3.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	4.07e-06	3.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOA1—type 2 diabetes mellitus	4.06e-06	3.86e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP1A2—type 2 diabetes mellitus	4.06e-06	3.86e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC2A1—type 2 diabetes mellitus	4.06e-06	3.86e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NFKB1—type 2 diabetes mellitus	4.01e-06	3.81e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	4e-06	3.8e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	4e-06	3.8e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	4e-06	3.8e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—type 2 diabetes mellitus	3.98e-06	3.78e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CYP3A4—type 2 diabetes mellitus	3.96e-06	3.76e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—type 2 diabetes mellitus	3.94e-06	3.74e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	3.93e-06	3.73e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	3.93e-06	3.73e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	3.93e-06	3.73e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GNB3—type 2 diabetes mellitus	3.89e-06	3.7e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.89e-06	3.7e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC2A4—type 2 diabetes mellitus	3.89e-06	3.7e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GCG—type 2 diabetes mellitus	3.89e-06	3.7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.89e-06	3.69e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—HMOX1—type 2 diabetes mellitus	3.88e-06	3.68e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	3.86e-06	3.67e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.84e-06	3.64e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	3.83e-06	3.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.83e-06	3.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CAT—type 2 diabetes mellitus	3.83e-06	3.63e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—type 2 diabetes mellitus	3.81e-06	3.62e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.76e-06	3.57e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	3.76e-06	3.57e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	3.75e-06	3.56e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	3.74e-06	3.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SRC—type 2 diabetes mellitus	3.73e-06	3.55e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL6—type 2 diabetes mellitus	3.73e-06	3.54e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—INS—type 2 diabetes mellitus	3.72e-06	3.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOB—type 2 diabetes mellitus	3.71e-06	3.53e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.66e-06	3.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GSTM1—type 2 diabetes mellitus	3.61e-06	3.43e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.6e-06	3.42e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.6e-06	3.42e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	3.6e-06	3.42e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—type 2 diabetes mellitus	3.58e-06	3.4e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	3.56e-06	3.38e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	3.56e-06	3.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—LPL—type 2 diabetes mellitus	3.55e-06	3.37e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	3.52e-06	3.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—INS—type 2 diabetes mellitus	3.51e-06	3.34e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SRC—type 2 diabetes mellitus	3.5e-06	3.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ADCY5—type 2 diabetes mellitus	3.47e-06	3.3e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	3.47e-06	3.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GPX1—type 2 diabetes mellitus	3.46e-06	3.29e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SRC—type 2 diabetes mellitus	3.45e-06	3.27e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.44e-06	3.27e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.42e-06	3.25e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	3.41e-06	3.24e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	3.41e-06	3.24e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—type 2 diabetes mellitus	3.41e-06	3.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	3.4e-06	3.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	3.4e-06	3.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	3.4e-06	3.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	3.4e-06	3.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CD36—type 2 diabetes mellitus	3.37e-06	3.2e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GNB3—type 2 diabetes mellitus	3.35e-06	3.19e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.35e-06	3.19e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—HMOX1—type 2 diabetes mellitus	3.34e-06	3.17e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPP2CA—type 2 diabetes mellitus	3.33e-06	3.16e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CAT—type 2 diabetes mellitus	3.29e-06	3.13e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—type 2 diabetes mellitus	3.27e-06	3.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.26e-06	3.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.26e-06	3.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	3.26e-06	3.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—ALB—type 2 diabetes mellitus	3.22e-06	3.06e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOB—type 2 diabetes mellitus	3.2e-06	3.04e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—MTHFR—type 2 diabetes mellitus	3.19e-06	3.03e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARA—type 2 diabetes mellitus	3.13e-06	2.97e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—type 2 diabetes mellitus	3.13e-06	2.97e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GSTM1—type 2 diabetes mellitus	3.11e-06	2.95e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—type 2 diabetes mellitus	3.08e-06	2.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3R1—type 2 diabetes mellitus	3.08e-06	2.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—NOS3—type 2 diabetes mellitus	3.08e-06	2.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—RELA—type 2 diabetes mellitus	3.07e-06	2.92e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—LPL—type 2 diabetes mellitus	3.05e-06	2.9e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AGT—type 2 diabetes mellitus	3.03e-06	2.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	3.03e-06	2.88e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—type 2 diabetes mellitus	3.02e-06	2.87e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—ADCY5—type 2 diabetes mellitus	2.99e-06	2.84e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CALM1—type 2 diabetes mellitus	2.98e-06	2.83e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GPX1—type 2 diabetes mellitus	2.98e-06	2.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOE—type 2 diabetes mellitus	2.97e-06	2.82e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	2.94e-06	2.79e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.94e-06	2.79e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOA1—type 2 diabetes mellitus	2.94e-06	2.79e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	2.93e-06	2.78e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CD36—type 2 diabetes mellitus	2.9e-06	2.76e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.89e-06	2.75e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	2.89e-06	2.74e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPP2CA—type 2 diabetes mellitus	2.87e-06	2.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	2.83e-06	2.69e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—type 2 diabetes mellitus	2.82e-06	2.68e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	2.8e-06	2.66e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	2.77e-06	2.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	2.77e-06	2.63e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.77e-06	2.63e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—MTHFR—type 2 diabetes mellitus	2.75e-06	2.61e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	2.73e-06	2.59e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	2.72e-06	2.58e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	2.7e-06	2.57e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	2.7e-06	2.57e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	2.7e-06	2.57e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARA—type 2 diabetes mellitus	2.7e-06	2.56e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	2.68e-06	2.55e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	2.68e-06	2.54e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.67e-06	2.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	2.64e-06	2.5e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	2.62e-06	2.49e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.62e-06	2.49e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AGT—type 2 diabetes mellitus	2.61e-06	2.48e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	2.61e-06	2.48e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	2.61e-06	2.48e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.59e-06	2.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—type 2 diabetes mellitus	2.59e-06	2.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CALM1—type 2 diabetes mellitus	2.57e-06	2.44e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOE—type 2 diabetes mellitus	2.56e-06	2.43e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	2.54e-06	2.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—INS—type 2 diabetes mellitus	2.54e-06	2.41e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOA1—type 2 diabetes mellitus	2.53e-06	2.4e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL6—type 2 diabetes mellitus	2.52e-06	2.39e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.51e-06	2.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	2.42e-06	2.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	2.42e-06	2.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	2.42e-06	2.3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SRC—type 2 diabetes mellitus	2.41e-06	2.29e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.41e-06	2.29e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	2.38e-06	2.26e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.36e-06	2.24e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	2.36e-06	2.24e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.35e-06	2.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—ALB—type 2 diabetes mellitus	2.33e-06	2.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—IL6—type 2 diabetes mellitus	2.32e-06	2.21e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—type 2 diabetes mellitus	2.32e-06	2.2e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	2.31e-06	2.19e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.29e-06	2.17e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.25e-06	2.14e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.24e-06	2.13e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—type 2 diabetes mellitus	2.23e-06	2.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3R1—type 2 diabetes mellitus	2.23e-06	2.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—NOS3—type 2 diabetes mellitus	2.23e-06	2.11e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.22e-06	2.11e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	2.22e-06	2.1e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	2.19e-06	2.08e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	2.19e-06	2.08e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—INS—type 2 diabetes mellitus	2.19e-06	2.08e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—type 2 diabetes mellitus	2.17e-06	2.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.16e-06	2.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—type 2 diabetes mellitus	2.14e-06	2.03e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.12e-06	2.01e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	2.1e-06	2e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	2.1e-06	2e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—type 2 diabetes mellitus	2.04e-06	1.93e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	1.95e-06	1.86e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3R1—type 2 diabetes mellitus	1.92e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—NOS3—type 2 diabetes mellitus	1.92e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—INS—type 2 diabetes mellitus	1.92e-06	1.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	1.81e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.81e-06	1.72e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	1.8e-06	1.71e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	1.78e-06	1.69e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	1.76e-06	1.67e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—type 2 diabetes mellitus	1.75e-06	1.67e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	1.73e-06	1.64e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.68e-06	1.6e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.68e-06	1.6e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	1.68e-06	1.59e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	1.65e-06	1.57e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL6—type 2 diabetes mellitus	1.63e-06	1.54e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	1.61e-06	1.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	1.61e-06	1.53e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	1.57e-06	1.49e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	1.55e-06	1.47e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.54e-06	1.46e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.5e-06	1.42e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	1.48e-06	1.41e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	1.46e-06	1.38e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—type 2 diabetes mellitus	1.42e-06	1.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	1.41e-06	1.34e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	1.39e-06	1.32e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	1.38e-06	1.31e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	1.37e-06	1.3e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	1.2e-06	1.14e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	1.18e-06	1.12e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	1.08e-06	1.03e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	1.04e-06	9.83e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	1.04e-06	9.83e-06	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—type 2 diabetes mellitus	1.02e-06	9.72e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	9.47e-07	8.99e-06	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—type 2 diabetes mellitus	8.82e-07	8.37e-06	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	7.72e-07	7.34e-06	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	4.76e-07	4.52e-06	CbGpPWpGaD
